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ABSTRACT
Transfusion-transmitted infections including hepatitis B virus (HBV) have been a major public
health concern worldwide. Occult HBV infection (OBI) is defined as the presence of HBV DNA in
the liver (with detectable or undetectable HBV DNA in the serum) of individuals who tested negative for HBsAg. Clinically, OBI is considered a risk for viral reactivation and possible transmission
of infection among individuals. It also contributes to liver disease progression and development of
hepatocellular carcinoma. Better knowledge and strategies to prevent, diagnose and manage must
be implemented in this field. The aim of this study was to estimate the prevalence of OBI among
multi-transfused patients in the northern districts of the occupied Palestinian territories. A prospective cross-sectional study was conducted in the period from August 2016 to May 2017 on 169 who
were negative for HBsAg and received more than 10 units of packed RBCs throughout their lives
were included in the study. Blood samples were tested for HBsAg, anti-HBs and anti-HBc by ELISA. Those positive to anti-HBc were then retested for HBV DNA, using an automated real-time
PCR method. Among the 169 HBsAg- negative sera, anti-HBc was detected in 35 patients (20.7%).
All anti-HBc-positive patients were HBV DNA-negative, and 27 (77.1%) of them were anti-HBspositive. Based on our results, it seems that there were no cases of OBI among poly-transfused patients with thalassemia and sickle cell anemia. However, to improve decisions concerning OBI
screening, especially in transfusion centers, more original studies with more precise laboratory
techniques and larger sample sizes are needed.
Keywords: Occult HBV; Anti-Hbc; HBV-DNA; Multi-Transfused Thalassemia.
INTRODUCTION
Over the past few decades, regular blood
transfusions and iron chelating therapies in
multiply-transfused patients such as patients
of thalassemia major, hemophilia or sickle
cell disease, have substantially improved
their overall survival [1]. However, these
recurrent transfusions may result in iron
overload and carry a definite risk of infection
with blood-borne viruses such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) [2].
Among these infections, HBV infection is the
most common disease commuted through
blood transfusion [3] and it remains the primary cause of liver cirrhosis and hepatocellu-

lar carcinoma (HCC), which are major contributors to global mortality.
While most infectious blood units are
removed by screening for hepatitis B surface
antigen (HBsAg), these assays remain unable
to detect infection in the pre-seroconversion
window period and in samples with very low
viral load after decades of chronicity or clinical recovery which is known as occult HBV
infection (OBI) [4]. OBI defined as the presence of hepatitis B virus DNA (HBV DNA)
without HBsAg, with or without the presence
of HBV antibodies [5]. Most OBIs are
asymptomatic and would only be detected by
systematic screening of large populations [4].
It has been a matter of debate for years and
may impact in several clinical aspects, in-
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cluding the liver disease progression, risk of
HCC, transmission of the infection by blood
transfusion or organ transplantation and its
acute reactivation when an immunosuppressive status occurs, all these clinical impact
make it very important to detect it especially
in high risk patients such as HCV patients
and multiply-transfused patient.
As the prevalence of OBI tends to be
higher where the prevalence of overt HBV
infection is high [6], there may be a relatively
high prevalence of OBI in Palestine since it is
categorized as an HB virus moderate endemic area, with the HB carrier rate ranging from
2-6 % [7]. All of these translating to an increasing number of patients who may be at
risk of chronic HBV infection and its consequences. Against this background, we sought
to investigate the prevalence of occult hepatitis B infection among multiply-transfused
patients in the North of Palestine, to enable
us make evidence-based recommendations
for effective HBV screening helping prevent
and control this prevalent health problem.
METHODS
A prospective cross-sectional study was
conducted in the period from August 2016 to
May 2017 on 169 patients of different hematological disorders. Patients who received
blood transfusions at three blood transfusion
centers located in the governmental hospitals

of Tulkarm (Thabet thabet governmental
Hospital), Nablus (Al-Watani governmental
Hospital) and Jenin (Shaheed Dr. Khalil Suleiman Governmental Hospital) cities were
included in the study.
Ethical consideration
Approvals were obtained from the Institutional Review Board Committee (IRB) at
Najah National University and the Palestine
Ministry of Health (MOH).
Participation in the study was voluntary
and informed written consent was obtained
from the patients before the study.
Selection of study population
Recipients of at least 10 units of Packed
Red blood cells (RBCs) throughout their
lives and are negative for HBsAg were included in the study. With the aid of structured data sheet, relevant demographic data
were obtained from participants, including
age, gender, age at the first transfused unit,
history of splenectomy, and use of chelating
agents. Lab tests results were also obtained
from the medical records and included
AST/ALT, and ferritin levels.
Selected participants were tested for the
presence of anti-Hepatitis B core antibodies,
anti- Hepatitis B surface antibodies, and Hepatitis B Virus DNA. (Figure 1).

169 Samples
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Negative

HBsAg ELISA
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nennnegative

134 Negative
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HBV DNA by RT-PCR

Figure (1): Flowchart of the Study.
Serologic analysis
The serological studies were done at the
Laboratory of An-Najah National University
Hospital in Nablus. All samples were
screened again for HBsAg using Dialab®
HBsAg ELISA kit (Dialab, GmbH, Austria).

Samples were screened for the presence of
total anti-HBc antibodies using One-step
ELISA kit (MBS, Milan Italy). Titers of antiHBs antibodies were measured using Dialab® HBsAb ELISA kit (Dialab, GmbH,
Austria). All serological tests were done according to manufacturers’ instructions.
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Hbv dna analysis
Plasma of participants who tested positive for anti-HBc antibodies were subjected
to Nucleic Acid Amplification Testing
(NAT). Viral DNA was extracted from plasma samples by Spin Column method using
an QIAamp Ultrasense Virus Kit (Qiagen,
Hilden, Germany) according to the manufacturer’s protocol. Plasma HBV DNA was
quantified by real-time Polymerase chain
reaction (PCR) using automated system.
Real-time PCR was performed with an ABI
7500 Detection System (Applied Biosystems,
Foster City, CA) using universal thermal profile. Real Time PCR results were also confirmed with another available Real Time
PCR assay: Abbott Real-Time HBV assay
with a lower detection limit of 10 IU/m (Abbott Laboratories, USA).
Data analysis
Data were statistically described in terms
of range, mean ± standard deviation (SD),
frequencies, and percentages when appropriate. Comparison of quantitative variables
between the study groups was done using the
Independent-Sample T Test. For comparing
categorical data, a Chi-square (χ2) test was
performed, and a probability value (P value)
less than 0.05 was considered statistically
significant. Binary logistic regression was
used, to asses significance among variables.
All statistical calculations were done using SPSS (SPSS Inc., Chicago, IL, USA)
version 21 for Microsoft Windows.
RESULTS
This study included 169 patients with
different hematological disorders who receive multiple blood units, of whom 83
(49.1%) were males and 86 (50.9%) were
females. Their ages ranged from 2- 71years
(mean of 20.2 ± 10.1) and half of them were
19 years of age and younger (Table 1)
Three centers were enrolled in our study;
86 patients (50.9%) from Nablus, 43 (25.4%)
from Jenin, 40 (23.7%) from Tulkarm. Regarding the diagnosis, there were 117 patients (69.2%) with thalassemia major, 15
(8.9%) thalassemia intermedia, 11 (6.5%)
sickle cell anemia, and 26 (15.4 %) sicklethalassemia. The mean number of transfused-

units was 235.5 ± 204.280. 82 patients
(48.5%) had undergone splenectomy. 140
patients (82.8%) were on chelating therapy.
(Table 1)
Table (1): Characteristics of participants.
Characters
Center

Jenin
Nablus
Tulkarm
Disorder
Thalassemia
major
Thalassemia
intermedia
Sickle cell
SickleThalassemia
Gender
Male
Female
Age
24 or less
More than
24
The mean number of transfused units
Splenectomy
Yes
No
Use of cheYes
lating agents
No

N

%

43
86
40

25.4
51
23.7

117

69.2

15

8.9

11

6.5

26

15.4

83
86
120

49.1
50.9
71

49

29

235.5 ± 204.3
82
87
140
29

48.5
51.5
82.8
17.2

Liver function tests were at the upper
limit of normal while ferritin levels were extremely high despite the fact the majority
(82.8%) of participants were on chelating
agents. (Table 2 &1)
Table (2): Results of biochemistry lab tests
of participants.
Lab test

Mean ± SD

ALT

42.7 ± 36.9

AST

48.9 ± 33.3

Ferritin

4187.7 ± 5292.1

Serological lab tests showed that seventy-five percent of patients were positive for
anti-HBsHBcAb was detected in 35 patients
(20.7%). (Table 3)
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Table (3): Results of Serological lab tests of
participants.

AntiHBc
AntiHBs

Positive
Negative
Positive
Negative

N

%

35
134
127
42

21
79
75.1
24.9

All anti-HBc-positive patients were
HBV DNA-negative; therefore, the prevalence of occult HBV is zero. Among the anti-

HBc-positive patients, 27 (77.1%) of were
positive for anti-HBs-positive. (Table 4)
In this study, no significant difference
was found between negative and positive
anti-HBc patients regarding their distribution
according to center, hematologic disorder,
gender, ferritin levels, ALT, or AST. (Table
4 &5)
However, after binary logistic regression
was used, no significance was found with any
variable.

Table (4): Characteristics of positive and negative HBcAb patients.
Variables
Anti-HBc
Positive: n (%) Negative: n (%)
Center

Jenin
Nablus
Tulkarm
Disorder
Thalassemia major
Thalassemia intermedia
Sickle cell
Sickle-Thalassemia
Gender
Male
Female
Age
24 or less
More than 24
Number of transfused units
Splenectomy
Yes
No
Use of chelating agents
Yes
No
Anti-HBs
Positive
Negative
ALT
AST
Ferritin

Age

24 or less
More than 24

10 (28.6)
20 (57.1)
5 (14.3)
29 (82.9)
0

33 (24.6)
66 (49.3)
35 (26.1)
88 (65.7)
15 (11.2)

1 (2.9)
10 (7.5)
5 (14.3)
21 (15.7)
21 (60)
62 (46.3)
14 (40)
72 (53.7)
20 (57.1)
100 (74.6)
15 (42.9)
34 (25.4)
322.97± 325.4
212.63± 151.98
23 (65.7)
59 (44)
12 (34.3)
75 (56)
33 (94.3)
107 (79.9)
2 (5.7)
27 (20.1)
27 (77.1)
100 (74.6)
8 (22.9)
34 (24.4)
41.84± 42.886
42.86± 35.293
52.84± 43.741
47.81± 30.173
3307.64±
4417.60±
3202.010
5700.776
Anti-HBs
Positive
Negative
91 (71.7)
29 (69)
36 (28.3)
13 (31)

P value
0.341

0.11

0.148
0.042*
0.004*
0.022*
0.044*
0.759
0.885
0.428
0.27

0.747
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DISCUSSION
Hepatitis B virus (HBV) infection is
the most common disease commuted
through blood transfusion and it is considered a global public health issue. Worldwide, approximately two billion people
showed serological evidence of past or current HBV infection. Investigations have
reported that a lot of individuals suffer
from the long term forms of HBV infection
including chronic, asymptomatic and occult
hepatitis B infection (OBI) [3]. According
to the World Health Organization (WHO),
more than 780 thousand people die every
year as a consequence of acute or chronic
HBV infection [8]. HBV has a higher residual risk of transmission by transfusion
than HCV or HIV. Also HBV is second
only to tobacco as a known human carcinogen [9].
While most infectious blood units are
discarded by screening for hepatitis B surface antigen (HBsAg)- the initial test used
in screening for HBV infection in Palestine
and many regions in the world- anti-HBc is
not being used as a screening test to determine previous exposure to the HBV. However, there is clear evidence that transmission by HBsAg negative components occurs during the serologically negative window period and the late stages of infection
[10].
The clinical impact of OBI especially
in high risk groups as described previously,
lead to the conduction of many studies in
this field aiming to gain better understanding and improving methods of detection.
Although The gold standard for OBI diagnosis is the detection of HBV DNA in the
DNA extraction from the liver, as covalently closed circular HBV DNA (ccc) DNA
(cccDNA) persists in the hepatocytes and
HBV DNA is sometimes detected in the
liver in the absence of HBV DNA in the
serum, obtaining liver tissue is an invasive
procedure and difficult to obtain in clinical
practice. Hence, serum HBV DNA assays
are widely used to diagnose OBI [11].

Many studies indicate that the potential
risk of acquiring occult hepatitis B virus
infection is higher in patients receiving
multiple and frequent blood transfusions.
The prevalence rates are widely variable
reported to range from 1% to 95% worldwide among different target groups and are
influenced by several factors (table 4) as
follows: 1) geographic differences (endemicity) (2) different patient characteristics,
including the presence of comorbid diseases such as chronic hepatitis C; and (3) and
the different diagnostic techniques used,
which have different sensitivity. The type
of sample used (liver or serum) or number
of samplings can also have some effect on
the diagnosis of OBI. Indeed, as serum
HBV DNA levels seem to fluctuate in OBI,
serial sample is more useful to identify OBI
[4].
To the best of our knowledge, this is
the first study that investigates the OBI
prevalence among multi-transfused patients
in Palestine. We included 169 multiply transfused patients diagnosed with thalassemia major, thalassemia intermedia, sickle
cell disease, and sickle-thalassemia; who
were HBsAg negative. 35 patients (20.7%)
found to be positive anti-HBc. All antiHBc-positive patients were HBV DNAnegative, and 27 (77.1%) of them were anti-HBs-positive. This suggests a cleared
previous HBV infection. Similar to our results, an Iranian cross-sectional study
showed that there was no detectable HBV
DNA among thalassemic patients who have
chronic hepatitis C infection [12]. In 2015,
a cohort Australian study found that only
0.69% of patients were HBsAg negative,
anti-HBc positive and HBV DNA positive
[13].
On the other hand, Singh et al. found
that OBI had a prevalence of 31.4% among
thalassemic patients [14]. Another more
recent Indian study reported that HBV
DNA was detected in 50 % of thalassemic
pediatric patients who had anti-HBc as the
only marker, and it was detected in 16.12
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% of cases who were sero-positive for both
anti-HBs and anti-HBc [15].
Among the Arab world, most studies
were done among different groups of
Egyptian population with different diagnostic methods. A study conducted in 2010
revealed that the prevalence of OBI among
thalassemic patients was 32.5% [9].
Despite no OBI cases were detected in
this study, attention must be directed toward those with anti-HBC positive, 35 cases (20.7%), since it was observed that antiHBc positive/HBV-DNA negative patients
showed a similar prevalence of severe liver
disease to anti-HBc positive/HBV-DNA
positive patients and a significantly higher
prevalence than anti-HBc negative cases.
This notion raises the clinical significance
of isolated positive anti-HBc antibody in
relation to liver disease [16].
Isolated anti-HBc is defined as the
presence of anti-HBc in the serum without
HBsAg or HBsAb. In our study, 8 patients
of the positive anti-HBc group (22.9%)
were anti-HBs negative. This has importance in clinical practice especially in candidate patients for chemotherapy and immunosuppressive therapy that requires further investigation because of the risk of
HBV reactivation. Isolated anti-HBc may
be due to resolved HBV infection in which
HBsAb had declined to an undetectable
level, testing during the window period or
chronic infection, in which HBsAg cannot
be detected due to protein mutation, makes
it undetectable by certain diagnostic assays
[17] so all these causes of isolated antiHBc only distinguishable if the additional
assays are done and measures of liver damage are taken into account. Measurement of
serum anti-HBs responses after the administration of HBV vaccination can be useful
to distinguish this serological profile [18].
Newly published Egyptian study revealed
that 15.19% of HBsAg negative patients
were positive for anti-HBc and anti-HBs
negative. Those anti-HBc positive patients
were tested for HBV DNA, and it was detected in 41.67% of them. Concluding that
OBI prevalence was 6.33% [17].

Patients who were born before 1992
had more positive anti-HBc results than the
younger (30.6% vs. 16.7%, P = 0.042).
This most likely supports the effectiveness
of the HBV vaccination program that was
adopted in Palestine in 1992. However, the
anti-HBs titers were not significantly related with the age of patients neither with
anti-HBc results.
Moreover, anti-HBc positive results
were significantly linked to the number of
transfused units (mean= 322.97 ± 325.421,
P =0.004). This result is in agreement with
that of Sabat et al. study, on 174 thalassemia patients in India, in which anti-HBc
was 12, 26.8, and 71.4% in patients who
received less than 40, 40-80, and greater
than 80 units of transfusions, respectively.
Their prevalence of anti-HBc was reported
to be 21.8% and anti-HBc was found to be
the only marker in six patients (3.45%)
[19].
Splenectomy has been a common management strategy for reducing regular
transfusion requirements, iron overload,
and extramedullary hematopoiesis in patients with hemoglobinopathies (e.g., thalassemia major, sickle thalassemia). 82 of
our patients (48.5%) had undergone splenectomy, and 28% of them were found to
be positive anti-HBc (vs. 13.8% among
patients who have spleen, P = 0.022). This
raises a question about the clinical impact
of splenectomy regarding increased risk of
viral infections. A cohort Australian research studied different infection outcomes
in 63 transfusion-dependent patients with
different hemoglobinopathies and recorded
30 cases of blood-borne viral infections.
The infection rate for hepatitis C, hepatitis
B, and HIV was 1.7 per 100 person-years
in splenectomized patients and 1.5 per 100
person-years in the non-splenectomized
patients; however, the p-value was not significant. 5 patients had been diagnosed
with HBV infection (acute and chronic)
prior to implementing of blood units
screening with HBsAg or HBcAb. 4 of
them were splenectomized [20]. Our results
showed that splenectomized patients had

Palestinian Medical and Pharmaceutical Journal (PMPJ). 2020; 5(1): 55-64 ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ

Adham Abu Taha, et al.  ــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ـــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــــ ــــــــــــ61

significantly higher numbers of transfusedunits than non-splenectomized patients (P
= 0.0001). This can probably provide an
explanation for the significance that was
found between the anti-HBc and splenectomy.
Interestingly, anti-HBc was significantly (P = 0.044) associated with chelating agents use, which are being used
among 82.8% of our patients. However, the
mean of ferritin level among those on chelation therapy was slightly higher than nonusers (4279.98 ± 5250.260 vs. 3742.37 ±
5563.354 ng/ml, P = 0.620) and as overall
both means were inappropriately very high.
Moreover, we noticed that the ferritin level
and liver enzymes, ALT and AST, were
significantly positively correlated (Table
5), which could be explained by hepatocytes damage due to transfusion-induced
Table (5): Correlations between different variables.
ALT
ALT

AST

Ferritin

Patient’s
Age

HBsAb Titer

Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N
Pearson Correlation
Sig. (2-tailed)
N

AST

iron overload. These findings are concurrent with the results of Suman et al. [21],
Asif M. et al. [22], and others. Based on
our notes, we believe these results may reflect an inadequate chelation or poor compliance from the patients. Unfortunately,
this makes them susceptible to ironoverload complications, ranging from multi-organ damage to vulnerability to bacterial and non-bacterial infections. There is an
evidence confirming the persistence and
resistance to treatment of viral hepatitis in
the presence of excess iron. Blumberg et al.
were the pioneers in describing a role for iron
in the modulation of hepatitis B virus. They
found that patients with higher levels of serum iron or ferritin were less likely to
achieve spontaneous recovery after acute
HBV infection [23].

Ferritin

Patient’s
Age

HBsAb Titer

1

.737**

.444**

-.043

.102

169
.737**

.000
169
1

.000
169
.324**

.580
169
.019

.187
169
.151

.000
169
.444**

169
.324**

.000
169
1

.807
169
.016

.050
169
-.056

.000
169
-.043

.000
169
.019

169
.016

.834
169
1

.471
169
.000

.580
169
.102

.807
169
.151

.834
169
-.056

169
.000

.997
169
1

.187
169

.050
169

.471
169

.997
169

169

** Correlation is significant at the 0.01 level (2-tailed).
AST: Aspartate Aminotransferase, ALT: Alanine Aminotransferase, HBsAb: Hepatitis B Surface Antibody.
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In this study, no significant difference
was found between negative and positive
anti-HBc patients regarding their distribution according to center, hematologic disorder, gender, ferritin levels, ALT, or AST.
However, after binary logistic regression was used, no significance was found
with any variable. This indicates that there
is no single significant predictor of the antiHBc presence due to the interactions between different variables.
Limitations of the study
There was a discrepancy between the
reported and actual number of patients attending these transfusion centres. The population of this study and its sample size is
relatively small. In addition, sickle cell patients and those patients who had splenectomy were not on a regular schedule to get
their transfusion. Moreover, patients’ medical records lacked essential relevant information including vaccination status,
presence of co-morbidities, and some laboratory tests. Lastly, although the detection of HBV DNA in liver biopsy is the
gold standard for diagnosis of OBI, it was
not practical or possible.
CONCLUSIONS
Our results showed no cases of OBI
among multi-transfused thalassemia and
sickle cell disease patients in the northern
of districts of Palestine. However, to improve decisions concerning OBI screening
and better understanding of the epidemiology of OBI and the significance of isolated
anti-HBc, further studies with larger sample size are needed. We also suggest considering anti-HBc screening in high risk
groups and a better follow up for such patients regarding proper vaccinations, regular physical examination and investigations, and prevention of transfusion related
complications.
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